European Network of Health Technology Assessment

European Network of Health Technology Assessment
Name	European Network of Health Technology Assessment
Abbreviation	EUnetHTA
Formation	2006
Type	Network
Headquarters	Brussels
Region served	Europe
Membership	National health technology assessment agencies

European Network of Health Technology Assessment

The European Network of Health Technology Assessment is a collaborative network that brings together national health technology assessment agencies, European Commission bodies, and regional health ministries to coordinate assessment of medical technologies. It aims to harmonize methodologies, reduce duplication across European Union member states, and support evidence-informed decisions in healthcare systems such as those in Germany, France, Italy, Spain, and United Kingdom. The network interacts with regulatory and policy actors including the European Medicines Agency, the World Health Organization, and supranational initiatives like the OECD.

History

EUnetHTA originated from discussions following the Lisbon Treaty era drive for stronger cross-border cooperation, formalized in early projects funded under European Commission research programmes and directives. Initial pilots and joint actions linked institutions such as the National Institute for Health and Care Excellence, Haute Autorité de Santé, Istituto Superiore di Sanità, and Finnish Medicines Agency to test joint assessment pathways. Subsequent phases coincided with milestone events including meetings at the European Parliament and collaborations with the European Court of Auditors on value assessment challenges. Over time, the network evolved through successive Joint Actions supported by Horizon 2020 and related funding mechanisms, expanding membership across Eastern Europe and the Nordic countries.

Structure and Governance

Governance combines a coordinating Secretariat based in Brussels with national focal points from agencies such as Zorginstituut Nederland, the Swedish Agency for Health Technology Assessment, and the Austrian Health Institute. Decision-making proceeds via steering committees, scientific boards, and working groups that mirror institutional structures found in organizations like the European Medicines Agency, European Centre for Disease Prevention and Control, and the Council of the European Union. Partner institutions include academic centres such as Karolinska Institutet, University College London, and Heidelberg University Hospital. Legal and policy oversight involves interactions with the European Commission Directorate-General for Health and Food Safety, national parliaments, and intergovernmental forums.

Scope and Activities

Activities span joint relative effectiveness assessments, scoping and prioritisation exercises, development of rapid assessment procedures, and production of core dossiers used by payers and HTA bodies across countries including Norway, Poland, Portugal, and Belgium. The network addresses technologies ranging from pharmaceuticals evaluated by the European Medicines Agency to medical devices subject to regulation influenced by the Medical Devices Regulation (EU). Projects often produce deliverables adopted by bodies such as the German Federal Joint Committee and inform procurement decisions in regions like Catalonia and Lombardy. Capacity building includes training with partners like Universitat de Barcelona, Ghent University, and Charles University.

Methodology and Guidelines

Methodological work draws on standards and reference models from agencies such as NICE, IQWiG, and the Canadian Agency for Drugs and Technologies in Health. Guidelines cover evidence synthesis, health economic modelling, indirect treatment comparisons, and patient-reported outcomes used in settings including Madrid Health Service and Saxony hospitals. Tools developed reference analytic frameworks comparable to those promoted by the Cochrane Collaboration, the Agency for Healthcare Research and Quality, and the International Society for Pharmacoeconomics and Outcomes Research. Quality assurance mechanisms engage peer review panels comprising experts from institutions like University of Copenhagen, Trinity College Dublin, and Medical University of Vienna.

Collaboration and Partnerships

Partnerships extend to international organisations including the World Health Organization, the Organisation for Economic Co-operation and Development, and the European Observatory on Health Systems and Policies. The network liaises with regulatory authorities like the European Medicines Agency and standards bodies such as ISO committees relevant to health technologies. Collaborative research involves universities like Oxford University, Sorbonne University, and Maastricht University, and coordination with payer networks such as the European Social Insurance Platform. Cross-sector collaborations include patient groups, exemplified by partnerships with European patient advocacy federations and clinical societies including the European Society of Cardiology and the European Respiratory Society.

Funding and Resources

Funding is a mix of European Programme grants, national contributions from member agencies such as the Swedish Ministry of Health and Social Affairs, and project-specific support from research initiatives like Horizon Europe. Resource allocation mirrors mechanisms used by entities like the European Commission and the European Investment Bank for cooperative public health ventures. Administrative and in-kind support is provided by participating institutions including Statens Serum Institut and national health research councils. Financial transparency and audit practices are aligned with procedures used by the European Court of Auditors and national audit offices.

Impact and Criticism

The network has influenced national decision-making, reducing redundant assessments and informing pricing and reimbursement policies in countries such as Greece and Ireland, while contributing to harmonised standards referenced by the European Commission and the Council of Europe. Criticism centres on perceived challenges to national sovereignty voiced by some member states, the variable uptake of joint reports by agencies like AIFA and HAS, and debates over methodological centralisation raised in forums such as the European Parliament and academic critiques from centres including London School of Economics and Bocconi University. Ongoing discussion addresses transparency, stakeholder representation, and balancing efficiency with local health system priorities emphasized by bodies like WHO EURO.

Category:Health technology assessment